Kornimate/medical-research-clean huggingface dataset:
internet-delivered emotion regulation individual therapy or adolescents (ierita) with self-injury within child and adolescent mental health services: pilot study

Conditions: Nonsuicidal Self-Injury; Self-Harm

Summary: the overall purpose of the study is to implement and evaluate ierita (internet-delivered emotion regulation individual therapy for adolescents) within child and adolescent mental health services for adolescents engaging in nonsuicidal self-injury (nssi) and to optimize treatment outcomes for those adolescents at risk of insufficient effects. the specific purpose of this pilot trial is to investigate feasibility in preparation for a larger trial.

self-injury without the intention to die is a growing and urgent global health crisis among youth. it is associated with substantial individual and societal costs, including increased risk of suicide attempts. scalable and evidence-based treatments are needed but lacking. digital interventions can be one promising solution. a recent study shows that a novel brief digital treatment, ierita, can be efficacious compared to treatment as usual only. however, not all respond sufficiently to standardized treatment, such as ierita, and continued self-injury entails risks and suffering. in this randomized controlled pilot trial, participants will be randomly allocated (1:1) to standard ierita or adaptable ierita. all participants will first receive standard ierita for four weeks. in treatment week four, non-remission will be predicted. adolescents allocated to adaptable ierita and classified as likely non-remission, will change to adapted ierita for the remaining eight weeks while all other participants will continue standard ierita. data will be collected pre-treatment, during treatment, post-treatment, one- three- and twelve-month post-treatment. the primary endpoint is one-month post-treatment. the main objective is to investigate the project's feasibility and test key components. the specific objectives are: 1. examine the feasibility of the project (treatment satisfaction and adherence, degree of participation in data collection, and level of resources). 2. explore the utility of adapted ierita compared to standard ierita for adolescents at risk of non-remission. 3. evaluate the performance of the algorithm predicting treatment non-remission. this project is sponsored by the swedish research council for health, working life, and welfare (number 2024-01916)

Eligibility criteria:
inclusion criteria: * 13-17 years old * at least one self-injury episode in the past three months * a parent willing to engage in the parent program exclusion criteria: * immediate suicide risk * global functioning corresponding to a rating ≤40 of the children's global assessment scale (cgas) * social problems needing immediate intervention (e.g., violence within the family) * ongoing dialectical behavior therapy for adolescents

Keywords: nonsuicidal self-injury internet-delivered treatment self-harm adolescence
the effects of bcrp q141k on allopurinol pharmacokinetics and dynamics

Conditions: Chronic Gout; Hyperuricemia

Summary: subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function bcrp q141k variant on allopurinol pharmacokinetics and pharmacodynamics.


Eligibility criteria:
inclusion criteria: * self-identified as asian/european ancestry * generally healthy with approved lab values for cbc,hfp,rfp, and uric acid * subjects with the abcg2 genotype, homozygous, heterozygous or homozygous for the major allele of rs2231142 will be recruited exclusion criteria: * vascular disease * renal impairment * medications/supplements that affect uric acid levels * pregnant or lactating women * prior history of allergic reaction to allopurinol or testing positive for hla-b\*5801 allele * risk of urinary or gastric retention or narrow-angle glaucoma * impaired hepatic function * evidence of anemia * evidence or diagnosis of congestive heart failure * smokers * subjects with a mutation other than rs2231142 in the abcg2 genotype * subjects taking hormonal contraceptives or other hormonal medications * evidence of recreational drug use as determined by questionnaire

Keywords: allopurinol
a study of jnj-87704916, as monotherapy and in combination for advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of jnj-87704916 as monotherapy and in combination with cetrelimab.


Eligibility criteria:
inclusion criteria: * for part 1: individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy; part 2: individuals with histologically or cytologically confirmed metastatic or locally advanced nsclc * have at least 1 injectable tumor * eastern cooperative oncology group (ecog) performance status of grade 0 or 1 * a participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study * thyroid function laboratory values within normal range exclusion criteria: * active disease involvement of the cns (example, primary central nervous system tumors, metastases, leptomeningeal disease). some exceptions are allowed * prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy * active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents * history of solid organ or hematologic stem cell transplantation * known positive test result for human immunodeficiency virus (hiv) or other immunodeficiency syndrome * history of grade 3 or higher toxic effects during prior treatment with immunotherapy or requirement of anti-tumor necrosis factor (tnf) or anti-interleukin 6 (il-6) agents to manage aes from prior treatment with immunotherapy * history of allergy to protein-based therapies or history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia)
does tracheal tube size affect patient's experience of postoperative sore throat and hoarseness

Conditions: Sore Throat; Hoarseness

Summary: how tube size affect patient's experience of postoperative sore throat and hoarseness

a randomised controlled study studying how tube size affect patient's experience of postoperative sore throat and hoarseness. the patients are randomised on the basis of gender. men are randomized to tube size 8.0 (usual) or 7.0. women are randomized to tube size 7.0 (usual) or 6.0.

Eligibility criteria:
inclusion criteria: * need for intubation * elective surgery * asa group i and ii * understands and speaks danish * give one's consent exclusion criteria: * known dementia * sari score \>4 * bmi \> 35 * acute intubation * attempt intubation \> 2 * known with previously difficult intubation

Keywords: postoperative tube size patient experience
resting-state functional mri for prediction of post-surgical prognosis in pediatric drug-resistant epilepsy

Conditions: Epilepsy

Summary: resting-state functional mri (r-fmri) has emerged in recent years to analyze resting networks. it allows, without active participation of the patients, to identify and analyze the different functional brain networks. the analysis of r-fmri can be done thanks to the graph theory, which is based on the based on the calculation of quantifiable parameters applied to the functional network studied, making it possible to assess its effectiveness. to the knowledge of the investigators, no study has used graph theory applied to r-fmri data in order to obtain parameters useful for the useful parameters for the individual prognosis of children who have to be operation for drug-resistant lesional epilepsy.


Eligibility criteria:
inclusion criteria: * patient aged between 6 and 18 years * receiving an mri for lesional drug-resistant epilepsy * affiliated or beneficiary of a social security plan * whose parents or guardians have received information about the study and have given their express consent to participate in the study exclusion criteria: * contraindication to absolute or relative mri (in particular, pregnant or breastfeeding women) * history of intracranial surgery * mri performed under general anesthesia
change of body composition and functional status following short-term pre-habilitation among morbidly obese patients before bariatric surgery

Conditions: Short Term Pre-habilitation Before Bariatric Surgery

Summary: observational study is conducted in patient under short term pre-habilitation before bariatric surgery.

observational study is conducted in patient under short term pre-habilitation before bariatric surgery. data on anthropometry (waist circumference), body compositions (weight, muscle mass, fat free mass, fat mass, fat percentage and basal metabolic rate (bmr)), and functional status (handgrips strength) are collected.

Eligibility criteria:
inclusion criteria: * obese or severe obese patients * candidates for short term pre-habilitation among morbid obese patients before bariatric surgery * aged more than 18 years old * malaysian * provided and signed informed consent exclusion criteria: * not a candidate for short term pre-habilitation among morbid obese patients before bariatric surgery * aged \<18 years old * non-malaysian * not able to provide informed consent * chronic renal failure

Keywords: obesity
abdominal wall tension in patients undergoing ventral hernia repair without component separation

Conditions: Hernia, Ventral; Hernia, Abdominal; Hernia Abdominal Wall

Summary: the purpose of this study is to use a scale to learn more about the tension of the abdominal wall in hernia repairs without component separation. 1. what is the abdominal wall tension for hernias repaired without a component separation? 2. what patient factors contribute to greater abdominal wall tension? 3. is there an association between abdominal wall tension before primary closure or bridging repair and patient outcomes? participants will be asked to allow their surgeon to use a tension scale to measure the tension of the abdominal wall during surgery.

this is a prospective cohort study. patients who undergo hernia repair without component separation will have their abdominal wall tension measured using a tension scale. the scale is an investigational (experimental) device that works by attaching to surgical clamps during surgery to measure the tension on the abdominal wall. the study operations will be performed at cleveland clinic by six hernia surgeons with advanced abdominal wall reconstruction training.

Eligibility criteria:
inclusion criteria: 1. patients who are planned to undergo ventral hernia repair without component separation 2. midline hernia exclusion criteria: 1. mesh excision for reasons other than mesh infection 2. prior component separation 3. isolated flank hernia 4. patients under the age of 18 years 5. pregnant patients
evaluation of appeal and impact of e-cigarettes among chronic smokers with smoking-related cancers

Conditions: Nicotine Dependence, Other Tobacco Product; Bladder Cancer; Lung Cancer; Cancer of Head and Neck

Summary: this study will test feasibility, in smokers with lung, head \& neck, and bladder cancers, that examines the effect of e-cigarette substitution, on measures of smoking-related toxicity and medical outcomes. the aim of the study is to determine the appeal of e-cigarettes compared to regular combustible cigarettes.

the aim of the study is to determine the appeal of e-cigarettes compared to combustible cigarettes as measured by the degree to which patients succeed in reducing their cigarette consumption over the 9 weeks they are supplied with product, along with their consumption of e-cigarettes. we will measure past use of e-cigarettes and cigarettes at baseline, 3, 6, 9, and 12 weeks. we will also assess the effect of e-cigarette substitution on toxicity by measuring expired carbon monoxide and urine nnal (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) , a carcinogenic metabolite of cigarette smoke.

Eligibility criteria:
inclusion criteria: 1. histological or cytological diagnosis of lung, head \& neck, or bladder cancer within the past 5 years. 2. ajcc (american joint committee on cancer) stages i-iv 3. daily smoking (at least 10 cigarettes per day for 10 years) and breath co (carbon monoxide) greater than or equal to 9 ppm 4. does not wish to quit smoking now (anyone wishing to quit smoking will be referred for smoking cessation counselling through the dhmc (dartmouth hitchcock medical center) program) 5. may be receiving anti-cancer agents 6. age 18 or older 7. fluent in english; 8. patient must be capable and willing to provide informed written consent for study participation; 9. able to participate in study visits exclusion criteria: 1. cancer surgery planned in the next 9 weeks; 2. treatment with radiation planned for the next 9 weeks, 3. actively trying to quit smoking, or planning to in the next 30 days. (if a subject reports that they plan to quit smoking in the next 30 days, we will call them after the 30 days to see if they are still trying to quit.) 4. any use of e-cigarettes in the past 30 days, 5. pregnant or trying to get pregnant.
mainz intracoronary database. the coronary slow-flow and microvascular diseases registry

Conditions: Coronary Artery Disease; Microvascular Dysfunction

Summary: primary goal of the registry is to collect prospective data on patients undergoing coronary angiography in mainz. following amendment of the procol, this study will also include patients who received an aborb bioresorbable scaffold for the therapy of de novo stenoses.

patients included in the registry will be contacted by telephone at 3,6,9, 12 months and 2, 5, 10 years after the procedure. in case coronary slow flow is shown at the index procedure, 39ml of blood will be drawn for further studies. according to the regulations of the province rheinland-pfalz, national law, and with the approval of the ethic commission of the landesärztekammer rheinland pfalz, patients (n=1000) will also be retrospectively entered in the database in an anonymous way. for these patients, no specific study procedure is foreseen and the micat database will be only used as a platform (database of anonymous data collected during routine clinical practice).

Eligibility criteria:
inclusion criteria: * clinical indication to coronary angiography exclusion criteria: * none

Keywords: microvascular disease coronary artery disease coronary artery disease, with or without microvascular dysfuntion
prediction of abatacept discontinuation using test reflecting immunological remission in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the objective of this study is to identify a panel of immunological molecular and cellular biomarkers able to predict the success of major dose-reduction or discontinuation of abatacept in rheumatoid arthritis patients

parameters studied at different time points (before initiation of abatacept if sample is available in our biocollection; prior to dose tapering; prior to discontinuation) acpa (anti-citrullinated proteins antibodies) repertoire -igg (immunoglobulins g) and/or iga auto-antibodies repertoire directed against major epitopes of well-known autoantigens b cell repertoire b cell repertoire and transcriptome of regulatory b lymphocytes, memory b cells and b cells targeting specific autoantigens. analysis of type i interferon signature expression levels of 7 type i interferon (ifn) response genes will be determined to calculate on type i ifn score

Eligibility criteria:
inclusion criteria: * rheumatoid arthritis (ra) patients (\> pr = 18 years) fulfilling the 2010 acr/eular criteria * associated to high levels (\> 3 x upper limit of normal in ua/ml) of acpa measured by the usual anti-ccp(cyclic citrullinated proteins)2 test at the start of abatacept treatment * receiving iv (intravenous) or sc (subcutaneous) abatacept alone or in combination with a conventional disease modyfying antirheumatic drugs (cdmard) (methotrexate, leflunomide, sulfasalasin in monotherapy or in combination) according to the usual scheme or in tapering phase * without intra-articular injections of corticosteroids during the last 6 months prior to down-titration of abatacept * having discontinued corticosteroids at he time of entrance in the study * in deep remission (disease activity score (das) 28 esr (or crp) \< 2.6 without clinical synovitis) since at least 1 year * in sonographic remission at the time of enrollment (absence of pd (power doppler)-positive synovitis on 28 joints defined by a score \< 2 on a 0-3 semi-quantitative scale for each joint) exclusion criteria: * age \< 18 years * ra negative for acpa (anti-citrullinated proteins antibodies) or not fulfilling acr/eular criteria * abatacept discontinuation due to serious adverse event, loss of efficacy or pregnancy project

Keywords: therapy discontinuation
variation in body composition on the fate of older subjects during ssr hospitalization

Conditions: Body Weight Changes

Summary: the aim of this study is to correlate weight variation as well as body composition with mortality and unscheduled readmission of geriatric population

weight loss in obese adults confers health benefits, while weight loss in the elderly is associated with an increased risk of mortality. there are a large number of studies associating weight loss and mortality but the relationships between changes in body composition (ratio between fat mass and lean mass) and mortality are often contradictory and poorly understood in elderly subject. the aim at this study is to request at this question.

Eligibility criteria:
inclusion criteria: * patient ≥70 years old * hospitalized in ssr for less than 7 days * no patient opposition exclusion criteria: * patient with a pacemaker * lake of nutritional assessment on admission * lake of assessment of autonomy at admission * patient under guardianship or curatorship * patient participating in another clinical research * patient for whom a short stay (\<21 days) is planned in ssr

Keywords: geriatric suite care and rehabilitation body composition
behavioral therapy development for methamphetamine abusers

Conditions: The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

Summary: the purpose of this study is...to assess whether placing a substance abuse intervention for hiv+ methamphetamine users within an hiv medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to hiv medication regimens.


Eligibility criteria:
inclusion criteria: 1. hiv-seropositive, gbm receiving medical treatment for hiv for at least 30 days prior to signing informed consent at the ucla care clinic, aged 18-65 2. willing to give informed consent and comply with study procedures; 3. willing to provide consent to contact treating physicians and pharmacies to assess adherence to hiv medications; 4. diagnosed with current methamphetamine abuse as determined by mini; and 5. interested in seeking treatment for their methamphetamine abuse and in participating in this research project. exclusion criteria: 1. unwilling to give, or withdrawal of, informed consent; 2. inability to understand nature of study; 3. a psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets dsm-iv-tr criteria for current bipolar disorder or a psychotic disorder); 4. current suicidal ideation or suicide attempt within the past 3 months; and 5. concurrent dependence on opiates, alcohol, or benzodiazepines as determined by mini. 6. total lack of any type of healthcare coverage. these potential participants will be given low-fee treatment referrals.

Keywords: behavior therapy methamphetamine
effect of calcium silicate based root canal medicament on inflammatory mediators

Conditions: Periapical; Infection

Summary: calcium hydroxide is generally preferred in endodontics as an intracanal medicament because of its antimicrobial and biological effects. however, the antimicrobial effect of calcium hydroxide is limited. the aim of this study was to investigate the effects of calcium silicate-based root canal medicament on the release of rankl/opg, tnf-α, pge-2 and tgf-β1 in root canal treated teeth with periapical lesions.

sixty patients were randomly divided into two groups using a web program according to the medication selected: calcium silicate based root canal medicament or calcium hydroxide based root canal medicament. after removing gutta-percha from the root canals, rankl/opg, tnf-α, pge-2 and tgf- β1 samples were taken from the interstitial fluid of the apical tissues using three paper points. at the second appointment, medicaments were removed and second sampling was performed using the same method. rankl/opg, tnf-α, pge-2 and tgf- β1 levels were measured by enzyme-linked immunosorbent assay and their ratios were calculated.

Eligibility criteria:
inclusion criteria: incisor, canine, and premolar teeth that had previously undergone root canal treatment (cases with persistent and secondary disease) and presented with a diagnosis of chronic apical abscess or asymptomatic apical periodontitis were included. incisor, canine, and premolar teeth with only 1 root canal were included in the study to avoid untreated extra root canals and difficulties in the preparation, obturation, and restoration of molar teeth and to make treatments more standardized.the patients had not used any antibiotics for 3 months before treatment, and patients were obviously free of systemic diseases. exclusion criteria: patients were excluded if teeth showed the presence of a root fracture or any swelling, ankyloses, or periodontal pockets deeper than 4 mm. teeth on which a rubber dam could not be performed were excluded. patients with allergy to ibuprofen or ciprofloxacin were also excluded.

Keywords: intracanal medicament intracanal dressing rankl osteoprotegerin tnf alpha tgf beta prostaglandin e2